Heart Failure

Study investigators used data from midlife checkpoints and late life checkpoints for participants without heart failure.

In this episode of Don't Miss a Beat, hosts Drs. Greene and Vaduganathan break down the new ACC/AHA/HFSA heart failure guidelines debuted at ACC.22 and compare the recommendations against those made in the European Society of Cardiology's 2021 heart failure guidelines.

Data show 80% of included patients had an increase of more than 20 points in Kansas City Cardiomyopathy Questionnaire summary scores.

No evidence of lower Lp(a)-associated risks in hormone therapy users versus nonusers was observed.

Don't Miss a Beat hosts Drs. Vaduganathan and Greene provide insight into the results of trials from ACC.22 late-breaking sessions they highlighted in the preview episode they recorded ahead of the American College of Cardiology's 71st Annual Scientific Session.

Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.

Data show omecamtiv mecarbil added to background therapy had no significant improvement regarding exercise capacity.

Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.

Peter Sogaard discusses the benefit of monitoring for arrhythmias in patients with non-STEMI heart attacks and the need to look at arrhythmias in a different light.

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

Lead SODIUM-HF investigator Justin Ezekowitz provides insight into the trial and why dietary interventions may still be important for heart failure care.

Larry Allen, MD, discusses some of ACC 2022's biggest contributions toward improving evidence-based care to patients with HF.

The majority of patients with HFrEF and RAASi-related hyperkalemia achieved optimal doses of RAASi when treated with patiromer.

No difference in the primary outcome was observed between those randomized to influenza vaccine compared to placebo.

Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.

Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.

Findings from SODIUM-HF suggest strategies to reduce dietary sodium intake to less than 1500 mg daily were not more effective than usual care in reducing hospitalization risk.

Findings from VALOR-HCM suggest more data is needed to assess the durability of improvement in septal reduction therapy eligibility over longer time periods.

New research suggests a consistent risk reduction of empagliflozin may be theorized independent of region or race categories.

Hospitalized HFrEF patients had a higher rate of the cardiovascular death or a worsening heart failure event than outpatients

Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.

Headed to ACC.22 this weekend or following along virtually? Hear from Don't Miss a Beat co-hosts Drs. Vaduganathan and Greene on their top picks from the late-breaking sessions at the upcoming American College of Cardiology meeting.

Strategies to improve enrollment of underrepresented populations were centered on study design and site selection, community engagement, and changing the research paradigm.

Greater increases were observed among members of racial and ethnic minority groups, with the highest increase among non-Hispanic Black individuals.

Dr. Bajona highlights the patient risks of HCM, new advances in treatment options, and the importance of screening efforts.